GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Cyclically Adjusted PS Ratio

New Ray Medicine International Holding (HKSE:06108) Cyclically Adjusted PS Ratio : 0.13 (As of Jun. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Cyclically Adjusted PS Ratio?

As of today (2024-06-07), New Ray Medicine International Holding's current share price is HK$0.053. New Ray Medicine International Holding's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was HK$0.40. New Ray Medicine International Holding's Cyclically Adjusted PS Ratio for today is 0.13.

The historical rank and industry rank for New Ray Medicine International Holding's Cyclically Adjusted PS Ratio or its related term are showing as below:

HKSE:06108' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.14   Max: 3.11
Current: 0.13

During the past 12 years, New Ray Medicine International Holding's highest Cyclically Adjusted PS Ratio was 3.11. The lowest was 0.07. And the median was 0.14.

HKSE:06108's Cyclically Adjusted PS Ratio is ranked better than
93.59% of 343 companies
in the Healthcare Providers & Services industry
Industry Median: 1.2 vs HKSE:06108: 0.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

New Ray Medicine International Holding's adjusted revenue per share data of for the fiscal year that ended in Dec23 was HK$0.030. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is HK$0.40 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


New Ray Medicine International Holding Cyclically Adjusted PS Ratio Historical Data

The historical data trend for New Ray Medicine International Holding's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Cyclically Adjusted PS Ratio Chart

New Ray Medicine International Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.58 0.17 0.12

New Ray Medicine International Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 - 0.17 - 0.12

Competitive Comparison of New Ray Medicine International Holding's Cyclically Adjusted PS Ratio

For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


New Ray Medicine International Holding's Cyclically Adjusted PS Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where New Ray Medicine International Holding's Cyclically Adjusted PS Ratio falls into.



New Ray Medicine International Holding Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

New Ray Medicine International Holding's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.053/0.4
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Ray Medicine International Holding's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, New Ray Medicine International Holding's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.03/114.7809*114.7809
=0.030

Current CPI (Dec23) = 114.7809.

New Ray Medicine International Holding Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 1.162 99.000 1.347
201512 0.986 100.600 1.125
201612 0.601 102.600 0.672
201712 0.162 104.500 0.178
201812 0.223 106.500 0.240
201912 0.071 111.200 0.073
202012 0.080 111.500 0.082
202112 0.201 113.108 0.204
202212 0.054 115.116 0.054
202312 0.030 114.781 0.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


New Ray Medicine International Holding  (HKSE:06108) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


New Ray Medicine International Holding Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines